This study was undertaken to determine the prevalence of Gram negative and Gram positive in various clinical samples collected during study and to analyze the antibiotic susceptibility patterns of various drugs against these isolates to find which drug offers the best solution against multidrug resistant Gram negative and Gram positive pathogens. In the current study, a total of 741 isolates were isolated from different clinical specimens between October 2018 to January 2019.  Antibiotic susceptibility testing were carried out according to the recommendations of Clinical Laboratory Standards Institute (CLSI) guidelines. Out of 741 clinical isolates, 575 (77.59%) were of Gram negative and 166 (22.40%) were of Gram positive. Among Gram negative pathogens, (n=575), the highest occurrence of pathogens was found in urine samples (81.57%) followed by stool (17.04%), pus (0.35%) and others 1.04%, whereas Gram positive (n=166) isolates were more dominant in sputum (24.70%) followed by pus/swab (23.49%), throat (18.07%), vagina (9.04%), synovial fluid (1.2%), each of ear swab, aural fluid, conjuctival fluid contributed to 0.6% and others making 21.69%. Further analysis of pathogens (n=741), Escherichia coli (63.43%) was the most dominant pathogen followed by Streptococcus pyogenes (9.18%), Streptococcus species (8.77%), Enterobacter species (8.64%), Proteus species (3.78%), Streptococcus haemolyticus (3.10%), Klebsiella species (1.48%) Staphylococcus species (1.35%) and Pseudomonas species (0.27%). Our susceptibility data revealed that Potentox was the most active antibacterial agent with the majority of isolates displaying 88.66% susceptibility, which is 20.10-54.25% high compared to other tested drugs. Levofloxacin appeared to be second most active agent (68.56%) followed by cefepime plus tazobactam (58.30%), meropenem (45.75%) and amikacin (34.41%). From the above results, it is evident that Potentox has enhanced in-vitro antibacterial activity and exhibited 20 to 54 % superiority over other drugs. Therefore, it can be a better choice to treat the infections caused by drug-resistant Gram negative and Gram positive pathogens in the clinical settings, and can be an important empiric consideration as a drug of choice to carbapenem.

Download this article as